Only three types of drug-resistant bacteria make the Center for Disease Control and Prevention’s list of “urgent” threats. One of them is gonorrhea.
That particular sexually transmitted infection is the target of a new drug being developed by Entasis, an antibiotics-focused spin-off from pharma giant AstraZeneca. But they’re getting help: their nonprofit partner, the Global Antibiotic Research and Development Partnership, will be funding the next round of trials and doing studies to ensure this drug keeps working for as long as possible. The partnership is GARDP’s first.
About the Author Reprints
Oh, thank God?
Before penicillin, when heavy metals were used to treat clap we used to say “One night with Venus, a lifetime with Mercury”. Better advice, keep it in your knickers until you get through sex ed 101.
It is interesting news as many drug resistant bacteria are immerging.So a step in this research will open door for other MDR organisms.